Back to Search
Start Over
No overall change in the rate of weight gain after switching to an integrase-inhibitor in virologically suppressed adults with HIV
- Source :
- AIDS. 34:109-114
- Publication Year :
- 2020
- Publisher :
- Ovid Technologies (Wolters Kluwer Health), 2020.
-
Abstract
- Excessive weight gain has been reported with integrase strand transfer inhibitors (INSTIs). We evaluated weight changes in virologically suppressed adults with HIV who switched from non-INSTI regimens to raltegravir (RAL)-containing or dolutegravir (DTG)-containing antiretroviral therapy.Retrospective single-centre cohort.Adults who switched to RAL or DTG before or between January 2015 and October 2017 were identified. Virologically suppressed, treatment-experienced (≥2 years) individuals, at least 6 months on INSTI, with weight measurements 2 years or less pre and postswitch were included. Our analysis used a random effects model with linear slope pre and post-INSTI with adjustment for age, sex, ethnicity, preswitch-regimen (protease inhibitor vs. nonprotease inhibitor), and RAL vs. DTG use.A total of 378 individuals, 81.2% male, 70.1% white ethnicity, median age of 49 years, median of four weight measurements per participant, and median weight and BMI at switch of 76.6 kg and 25.3 kg/m, respectively, were included. Weight increased by an average of 0.63 kg/year (95% confidence interval 0.17-1.09) preswitch with no overall change in rate of weight gain postswitch [+0.05 kg/year (-0.61-0.71, P = 0.88)]. In our adjusted model, a transition from minimal weight change to weight gain postswitch was isolated to older individuals though this lacked statistical significance [e.g., +1.59 kg/year (-0.26-3.45) if aged 65 years]. Our findings did not differ by sex, ethnicity, preswitch regimen, or RAL vs. DTG. Similar results were seen for BMI and after adjusting for fixed nucleoside/nucleotide reverse transcriptase inhibitor backbone.We found no clear evidence of an overall increase in rate of weight gain following switch to INSTI in virologically suppressed individuals.
- Subjects :
- Adult
Male
0301 basic medicine
Sustained Virologic Response
Pyridones
Immunology
Human immunodeficiency virus (HIV)
Integrase inhibitor
HIV Infections
Weight Gain
medicine.disease_cause
Piperazines
Strand transfer
Young Adult
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Raltegravir Potassium
Oxazines
Humans
Immunology and Allergy
Medicine
HIV Integrase Inhibitors
030212 general & internal medicine
Aged
Retrospective Studies
biology
Drug Substitution
business.industry
Middle Aged
Raltegravir
Virology
Antiretroviral therapy
Integrase
Treatment Outcome
030104 developmental biology
Infectious Diseases
chemistry
Dolutegravir
HIV-1
biology.protein
Female
medicine.symptom
business
Heterocyclic Compounds, 3-Ring
Weight gain
medicine.drug
Subjects
Details
- ISSN :
- 02699370
- Volume :
- 34
- Database :
- OpenAIRE
- Journal :
- AIDS
- Accession number :
- edsair.doi.dedup.....27cea8e80e7916cf434b505baa7c8503